Abstract
1700
Objectives Vascular endothelial growth factor receptor (VEGFR) is highly expressed in human thyloid gland. In mice normal capillalies of thyroid is known to regress after anti-VEGF therapy and grow back within 2 week after cessation of treatment (Kamba Am J Physiol Heart Circ Physiol, 2009). However, the effect of BEV on normal organ blood flow has been rarely reported (Van der Veldt, Cancer Cell, 2012). The purpose of this study was to evaluate a change in thyroid gland blood flow after chemotherapy with anti-VEGF agent bevacizumab (BEV) in humans using 15O -H2O PET.
Methods Four patients with advanced adenocarcinoma of lung underwent a 10 min dynamic 15O-H2O PET scan before and 1-2 days after administration of carboplatin (CBDCA)+paclitaxel+BEV or CBDCA+pemetrexed+ BEV. One patient among four received posttreatment PET three times: at 1, 18 and 39days after the beginning of chemotherapy. Using nonlinear regression, 15O -H2O thyroid gland time activity curves were fitted to the single-tissue compartment model using image derived input functions, which were determined using volumes of interest over ascending aorta.
Results The mean (SD) blood flow of thyroid gland were 1.1 (0.55) to 0.60(0.12) ml/min/cm3 at baseline and 1-2 day after the treatment, respectively. Statistically no significant changes were observed before/after the treatment, while the blood flow of lung cancer was decreased (Yanagawa RSNA annual meeting 2015). In the patient who received posttreatment PET three times, the blood flow of thyroid gland was decreased 1 day after the treatment, and tended to recover at 18 and 39 days, while the blood flow of lung cancer remained decreased.
Conclusions Blood flow of normal thyroid gland was not decreased significantly after the chemotherapy with BEV. The one case in which thyroid blood flow recovered suggests the reversibility of thyroid gland blood flow after the administration of BEV.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.